had shown how cetuximab‐treated CRC cell lines have transiently higher levels of mutagenic polymerases and lower levels of MMR proteins14 while another study on COSMIC signatures associated with cetuximab‐treated CRC showed no significant increase in SBS3 or SBS6 or SBS15 signatures, which are associated with loss of MMR activity.42 Here, MRC1 is linked to colorectal carcinoma.